Fresenius and WuXi Biologics form biosimilars deal

Fresenius SE & Co. KGaA announced a development partnership with WuXi Biologics to enhance its biosimilars portfolio. The exclusive agreement grants Fresenius option rights for up to 37 potential biosimilar candidates over the next ten years, expanding its current 29 molecules to potentially 66. This deal is the largest development agreement in the biosimilars industry.

Fresenius will compensate WuXi Biologics on a fee-for-service basis. The portfolio will span 13 therapeutic areas, including neurology, nephrology, oncology, and immunology, among others. Initial development efforts will focus on polatuzumab vedotin and teprotumumab. Fresenius will hold global commercialization rights and retain full economic ownership of the commercialized products.